136 results
Page 5 of 7
6-K
EX-99.1
x6l5lp5
14 Sep 20
InflaRx Announces Initiation of Phase III Part of Phase II/III Clinical Trial with IFX-1 in Severe COVID-19 Induced Pneumonia
7:36am
6-K
EX-99.1
7o3uwl6vfi9 90
6 Aug 20
InflaRx to Present at Upcoming Virtual Investor Events
7:35am
6-K
EX-99.3
zsbtdjtcr6wgxcy4zmz9
30 Jul 20
Current report (foreign)
7:36am
6-K
EX-99.1
ud3hkz jvqv04n1hl48e
30 Jul 20
Current report (foreign)
7:36am
6-K
EX-99.2
r60vr9 dft
30 Jul 20
Current report (foreign)
7:36am
6-K
EX-99.1
1hkdsoxigzxih
21 Jul 20
InflaRx Announces Decision to Enter Phase III Development of IFX-1 in Severe COVID-19 Induced Pneumonia
7:35am
424B5
83zm6km
20 Jul 20
Prospectus supplement for primary offering
9:21am
F-3
4j4e mlzwy
8 Jul 20
Shelf registration (foreign)
12:00am
6-K
EX-99.1
ji71g2jgl
17 Jun 20
InflaRx Reports Encouraging Topline Results from the Exploratory Phase II Part of the Adaptive Randomized Phase II/III Trial of IFX-1 in COVID-19
7:30am
6-K
EX-99.3
859k9sw3g9hpn0xvkd9c
21 May 20
Current report (foreign)
8:09am
6-K
EX-99.2
3l1y4px0atm dw
21 May 20
Current report (foreign)
8:09am
6-K
EX-99.1
08q9ei7h2kgmlad
21 May 20
Current report (foreign)
8:09am
6-K
EX-99.1
nakb1g6f0z 5l
29 Apr 20
InflaRx Reports Full Year 2019 Financial & Operating Results
8:00am
6-K
EX-99.1
gxwpyx vai6uzh
9 Apr 20
Controlling inflammation LIFESCI CAPITAL ALPHA SERIES CONFERENCE 2020
7:26am
6-K
EX-99.1
lkloprld
31 Mar 20
Current report (foreign)
9:29pm
6-K
EX-99.1
q06tny95ki6sd0u7 h02
26 Feb 20
InflaRx Announces Positive Initial Data from Ongoing Phase IIa Open Label Study with IFX-1 in Patients Suffering from Pyoderma Gangraenosum
7:15am
6-K
EX-99.2
7wr4jih5kvmfi7l
26 Feb 20
InflaRx Announces Positive Initial Data from Ongoing Phase IIa Open Label Study with IFX-1 in Patients Suffering from Pyoderma Gangraenosum
7:15am
6-K
EX-99.3
badzro
26 Feb 20
InflaRx Announces Positive Initial Data from Ongoing Phase IIa Open Label Study with IFX-1 in Patients Suffering from Pyoderma Gangraenosum
7:15am